Advertisement

Antimycotic Treatment of Oral Candidiasis in Warfarin Users

Published:November 08, 2020DOI:https://doi.org/10.1016/j.amjmed.2020.10.018
      • Miconazole oral gel and systemic fluconazole are associated with marked increases in international normalized ratio (INR) during warfarin use.
      • Nystatin oral solution does not appear to interact with warfarin treatment.

      Abstract

      Purpose

      Azole antimycotics and nystatin oral solution are used to treat oral candidiasis. Azoles inhibit cytochrome (CYP) P450-dependent metabolism of warfarin, which could increase the anticoagulant effect of warfarin. Nystatin is not expected to interfere with warfarin metabolism, but current data are conflicting. With this study, we aimed to explore the potential drug-drug interactions between warfarin and azole antimycotics used in the treatment of oral candidiasis, that is, systemic fluconazole, miconazole oral gel, and nystatin oral solution.

      Methods

      By linking clinical data on international normalized ratio (INR) measurements with administrative data on filled prescriptions of warfarin and antimycotics during 2000-2015, we explored INR changes in warfarin users relative to initiation of systemic fluconazole (n = 413), miconazole oral gel (n = 330), and nystatin oral solution (n = 399).

      Results

      We found a significant increase in mean INR of 0.83 (95% confidence interval [CI] 0.61-1.04) and 1.27 (95% CI 0.94-1.59) following initiation of systemic fluconazole and miconazole oral gel, respectively. Also, the proportion of patients experiencing an INR-value above 5 was increased after initiation of fluconazole (from 4.3% to 15.3%) and miconazole (from 5.5% to 30.1%). INR was unaffected by initiation of nystatin oral solution (mean change 0.08; 95% CI -0.10 to 0.25).

      Conclusion

      Initiation of systemic fluconazole and miconazole oral gel was associated with increased INR in warfarin users. A similar association was not found for nystatin oral solution, which thus appears to be the safest alternative when treating oral candidiasis in warfarin users.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Johnson JA
        Warfarin pharmacogenetics: a rising tide for its clinical value.
        Circulation. 2012; 125: 1964-1966
        • Holbrook AM
        • Pereira JA
        • Labiris R
        • et al.
        Systematic overview of warfarin and its drug and food interactions.
        Arch Intern Med. 2005; 165: 1095-1106
        • Hellfritzsch M
        • Pottegard A
        • Pedersen AJ
        • et al.
        Topical antimycotics for oral candidiasis in warfarin users.
        Basic Clin Pharmacol Toxicol. 2017; 120: 368-372
        • Garcia-Cuesta C
        • Sarrion-Pérez MG
        • Bagán JV
        Current treatment of oral candidiasis: a literature review.
        J Clin Exp Dent. 2014; 6: e576-e582
        • Kovac M
        • Mitic G
        • Kovac Z
        Miconazole and nystatin used as topical antifungal drugs interact equally strongly with warfarin.
        J Clin Pharm Ther. 2012; 37: 45-48
      1. Engell AE, Svendsen ALO, Lind BS, et al. Drug-drug interaction between warfarin and statins: a Danish cohort study [e-pub ahead of print]. Br J Clin Pharmacol. Accessed April 4, 2020.

        • Pottegård A
        • Schmidt SAJ
        • Wallach-Kildemoes H
        • Sørensen HT
        • Hallas J
        • Schmidt M
        Data resource profile: the Danish National Prescription Registry.
        Int J Epidemiol. 2017; 46 (798-798f)
        • Palareti G
        • Leali N
        • Coccheri S
        • et al.
        Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.
        Lancet. 1996; 348: 423-428
        • Niwa T
        • Shiraga T
        • Takagi A
        Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
        Biol Pharm Bull. 2005; 28: 1805-1808
        • Schafer-Korting M
        • Blechschmidt J
        • Korting HC
        Clinical use of oral nystatin in the prevention of systemic candidosis in patients at particular risk.
        Mycoses. 1996; 39: 329-339
        • Hellfritzsch M
        • Lund LC
        • Ennis Z
        • et al.
        Ischemic stroke and systemic embolism in warfarin users with atrial fibrillation or heart valve replacement exposed to dicloxacillin or flucloxacillin.
        Clin Pharmacol Ther. 2020; 107: 607-616